Search Results
Your search for what matches 6123 pages
Showing 1351 - 1400Pembrolizumab/Entinostat for Metastatic Uveal Melanoma
In the phase II PEMDAC study, researchers showed that the combination of the PD-1 inhibitor pembrolizumab and the histone deacetylase (HDAC) inhibitor entinostat resulted in durable responses in a small group of patients with metastatic uveal melanoma. These findings were published by Ny et al in...
Early-Stage Research on Dual-Action Estrogen Receptor Inhibitors for Breast Cancer
A set of compounds developed by scientists at Scripps Research target estrogen-sensitive breast cancer cells in new ways, potentially creating better options for patients with treatment-resistant cancers. More information on these dual-mechanism estrogen receptor inhibitors was published by Min et...
Study Examines Link Between in Utero Events and Risk of Colorectal Cancer in Adult Offspring
Infants whose mothers were obese during pregnancy may have a heightened risk of developing colorectal cancer later in life, according to new research published by Murphy et al in the journal Gut. Obesity is already a well-established risk factor for colorectal cancer, and several studies suggest...
Are Triplets Necessary for BRAF-Mutated Melanoma?
Where does triplet therapy fit in the treatment of patients with stage IV BRAF-mutated melanoma? Is there strong evidence for combining a BRAF inhibitor, MEK inhibitor, and checkpoint inhibitor? Ragini Kudchadkar, MD, Chair of the Protocol Review and Monitoring Committee at Winship Cancer Institute ...
Liquid Biopsy Is Changing Colon Cancer Management
The measurement of circulating tumor DNA (ctDNA) is changing the way gastrointestinal cancers are managed, according to Bassel F. El-Rayes, MD, Professor and Vice Chair for Clinical Research in the Department of Hematology and Oncology, Emory University, and Associate Cancer Center Director,...
Two Studies Explore the Role of Primary Care Providers in Effective Cancer Care
Communication between patients and their primary care providers is key to ensuring effective cancer care, both before diagnosis and after treatment, according to two recent papers authored by University of Michigan Rogel Cancer Center researchers. Although each study analyzed different stages of...
Leland Chung, PhD, Distinguished Mentor and Urologic Oncology Research Scientist, Dies at 80
Talk to anyone who knew Leland Chung, PhD, and you’ll hear the same descriptions of the famed scientist: warm, humble, gracious, brilliant, innovative. Dr. Chung, who served as Director of the Urologic Oncology Research Program at Cedars-Sinai Cancer in Los Angeles for 12 years and was Professor in ...
I’m a Two-Time Breast Cancer Survivor, and the Experience Has Been Life-Altering
Even before my breast cancer diagnosis in early 2002, the year was shaping up to be life-altering for me and my family. We had moved from Seattle to Houston for a new career opportunity for my husband and were just settling into our new home when I felt a pea-sized nodule in my left breast during a ...
Neuroendocrine Tumor Specialist Pamela Kunz, MD, Looks to Promote Equity in the Workforce
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Pamela Kunz, MD, Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center. Dr. Kunz is an international leader in the clinical care of patients with neuroendocrine...
New Guideline Provides Clarity on Timing, Treatment of Axilla in Early-Stage Breast Cancer
ASCO and Ontario Health (Cancer Care Ontario) have collaborated to release a new clinical practice guideline on the management of the axilla in early-stage breast cancer.1 “A lot has changed in the past several years with regard to de-escalating the amount of treatment women are offered in the...
Outcomes Notably Improving for Adult ALL
Outcomes in adults with acute lymphoblastic leukemia (ALL) are almost rivaling those in pediatric ALL, thanks to the benefits achieved by incorporating blinatumomab and inotuzumab into chemotherapy regimens. New ways of administering the chemotherapy component are also increasing tolerability and...
Does Antibiotic Exposure Affect Response to First-Line Chemoimmunotherapy in Patients With NSCLC?
In an international, multicenter study, researchers evaluated the impact of prior and concurrent antibiotic exposure in a cohort of patients with advanced non–small cell lung cancer (NSCLC) treated with first-line chemoimmunotherapy combinations. In contrast to what has been reported in patients...
Eric Deutsch, MD, PhD, Comments on the Averectal and AVANA Trials in Rectal Cancer
Eric Deutsch, MD, PhD, Professor and Chair of Radiation Oncology at Gustave Roussy, Villejuif, France, commended the speakers for conducting trials whose results he found “very interesting.” The Averectal trial involved a short course of radiation with modified FOLFOX-6 (oxaliplatin, fluorouracil...
Study Finds Cannabis Use Is Lower Among Patients With Cancer Than Those With No Cancer History
In a study published by Do et al in the journal Cancer, researchers analyzed data from nearly 20,000 people over a span of 4 years. They found that reports of cannabis use peaked at 9% for those with a cancer history, compared to 14% among people with no cancer history. “Even when we looked at...
Gut Microbiome and Cancer
In recent years, the gut microbiome has garnered considerable attention as a scientific field, with far-reaching potential for clinical good. The trillions of microorganisms that inhabit the digestive tract form an incredibly complex community, which participates in countless interactions with its...
Experimental Small-Molecule Inhibitor May Improve Responses to Cellular Therapies in Advanced CLL
Too many “exhausted” T cells left in the wake of aggressive chemotherapy regimens for patients with advanced chronic lymphocytic leukemia (CLL) make it more challenging for chimeric antigen receptor (CAR) T-cell therapy to do its job. Now, a new study from researchers at the Perelman School of...
S. Vincent Rajkumar, MD, on Multiple Myeloma: Defining Cure
S. Vincent Rajkumar, MD, of the Mayo Clinic, talks about how, in light of the fact that multiple myeloma has been turned into a chronic disease for many people, what it means to “cure” patients; the difference between curable and cured in multiple myeloma; and key studies he is involved in that...
Do Muscle-Strengthening Activities Plus Aerobic Activities Reduce Cancer Mortality?
Regular muscle-strengthening exercises associated with aerobic activities can reduce cancer mortality, according to a systematic review of epidemiologic studies published by Nascimento et al in the International Journal of Behavioral Nutrition and Physical Activity. Workouts with activities like...
Outcomes and Behaviors Among Women Receiving or Declining Their Breast Cancer Polygenic Risk Score
A recent study examined patient-reported outcomes and risk-management behaviors of women choosing to receive or decline their breast cancer polygenic risk scores (PRS). The findings were published by Tatiane Yanes, PhD, and colleagues in Genetics in Medicine. The research aimed to look at how the...
The Patient We See and the Person We May Not
A middle-aged patient was referred to our clinic with a mass in his liver. It had been detected the preceding year, and the patient underwent a battery of investigations with scans and biopsies to reach a diagnosis of metastatic lesion of the liver. After appropriate consultations with oncologists, ...
Expert Point of View: Leslie Popplewell, MD
“Naratuximab emtansine plus rituximab appears to be an effective and well tolerated combination in a heavily pretreated population. The results of the study are very promising,” said Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell...
Zanubrutinib Superior to Ibrutinib for CLL/SLL in Phase III ALPINE Trial
Zanubrutinib, a second-generation Bruton’s tyrosine kinase (BTK) inhibitor, significantly improved response rates and delayed disease progression as compared with the standard of care, ibrutinib, in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma...
RATIONALE 302: Tislelizumab Improves Overall Survival as Second-Line Treatment of Esophageal Cancer
In the phase III RATIONALE 302 trial, the novel anti–PD-1 antibody tislelizumab, being developed in China, improved overall survival vs chemotherapy as second-line therapy for esophageal squamous cell carcinoma, according to Jaffer Ajani, MD, of The University of Houston MD Anderson Cancer Center,...
Facing the Trauma of Colorectal Cancer
I first noticed blood in my stool when I was in the 8th grade. My mom and I did an Internet search and were relieved to find that the cause was most likely nothing more serious than hemorrhoids, so I put the problem out of my mind. I played volleyball and had an active social life, and the...
From Istanbul to Orange County, an Oncologist’s Journey to a Leadership Role in Quality Care
Pelin Cinar, MD, MS, was born and reared in Istanbul, Turkey. “My father ran a small furniture business, and my mother was a homemaker. However, I had a distant cousin who was an obstetrician-gynecologist, but he did house calls and treated any number of health issues in the community. Early on, I ...
Is Disease-Free Survival the Best Endpoint for Adjuvant Nivolumab in High-Risk, Muscle-Invasive Urothelial Carcinoma?
The role of adjuvant treatment for invasive, high-grade bladder cancer remains controversial and challenging. Sternberg et al reported a statistically significant progression-free survival benefit from adjuvant combination gemcitabine/cisplatin (GC) or MVAC (methotrexate, vinblastine, doxorubicin, ...
An Egyptian Surgical Oncologist Urges Global Cooperation to Achieve Equitable Cancer Care
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Ashraf Zaghloul, MD, DrPH, Professor at the National Cancer Institute of Egypt and President of the Egyptian Society of Surgical Oncology. Dr. Zaghloul was born in 1956 in ...
Expert Point of View: Chris Verslype, MD, PhD
The invited discussant of the RATIONALE 208 trial, Chris Verslype, MD, PhD, Professor of Medicine at University Hospitals Leuven in Belgium, said tislelizumab is an “active and safe” investigational PD-1 antibody, “comparable to other PD-1 agents.” In particular, he noted, the results of RATIONALE ...
Defining Cure in Multiple Myeloma
Recently, The ASCO Post published an article titled "Defining Cure in Multiple Myeloma: A Conversation With S. Vincent Rajkumar, MD." On this episode of the podcast, Dr. Rajkumar, of the Mayo Clinic, talks about what it means to “cure” patients, in light of the fact that multiple myeloma has been...
Study Shows Cancer Trials Adapted Rapidly During the COVID-19 Pandemic
Cancer clinical trial research rapidly adapted to the circumstances of enrolling and treating patients in clinical trials during the COVID-19 pandemic, according to findings from a study of enrollment during 2020 and early 2021 published by Joseph M. Unger, PhD, and colleagues in JAMA Network ...
Expert Point of View: Lisa Carey, MD
NEOTALA’s invited discussant, Lisa Carey, MD, the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research and Deputy Director of Clinical Sciences at the University of North Carolina-Chapel Hill, saw the findings as part of a bigger trend toward reducing the use of...
How Climate Change Is Impacting Cancer Care and What Can Be Done to Reduce Oncology’s Footprint on the Environment
Worldwide, the global average surface temperature has risen at a similar rate of 0.17°F per decade since 1901, with the warmest year on record occurring in 2016 and the second warmest occurring in 2020. However, according to NOAA, since the late 1970s, the United States has warmed faster than the...
Study Explores Cost-Effectiveness of CHOP Therapy for Patients With DLBCL in Sub-Saharan Africa
In a clinical trial conducted in Malawi, researchers found that combination chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) provided curative benefit compared to current standard-of-care therapy in people diagnosed with diffuse large B-cell lymphoma (DLBCL)—and...
Breast Cancer in 2030: Predictions From a Breast Cancer Luminary
According to George W. Sledge, Jr, MD, FASCO, Professor of Medicine in the Division of Oncology at Stanford University Medical Center, by the beginning of the next decade, clinicians will be aided by the use of artificial intelligence (AI) in many facets of care and by the approval of a wave of new ...
Expert Point of View: Fabrice André, MD, PhD
Fabrice André, MD, PhD, Director of Research and Professor of Medical Oncology at Institut Gustave Roussy, Villejuif, France, commented on the two studies that used the MammaPrint 70-gene signature to identify patients for de-escalation or escalation of endocrine therapy.1,2 The push to...
I’m Alive by Sheer Force of Will—and a Lot of Luck
From the moment I felt a searing pain go through my right breast, I had a premonition that something was very wrong. Although I couldn’t feel anything unusual when I did a breast self-exam, I made an appointment with my gynecologist for a more thorough clinical breast exam and a mammogram. Because...
Expert Point of View: Lisa Horvath, PhD, MBBS
Invited study discussant Lisa Horvath, PhD, MBBS, a medical oncologist at Chris O’Brien Lifehouse, University of Sydney, Australia, commented on the results of the EORTC 1333/PEACE III trial: “It was good to see the fracture rate in the radium-223 arm did, in fact, improve. However, what I found...
The Compelling Story of Cystic Fibrosis and the Dawn of Precision Medicine
Woe to the child who tastes salty from a kiss on the brow” was a forbidding prophecy from Medieval Europe, presaging unknown disease. Today, we know that salty skin is a telltale sign of cystic fibrosis in children, a disease that eluded medical identification until 1938, when an American...
Expert Point of View: Jaishri O. Blakeley, MD
Invited study discussant Jaishri O. Blakeley, MD, Director of the Johns Hopkins Comprehensive Neurofibromatosis Center, Baltimore, changed the title of her talk to “Finding Needles in Haystacks,” “because this is what we do with CNS [central nervous system] tumors,” she told listeners. “ALK...
Expert Point of View: Amit M. Oza, MD, MBBS
Invited discussant of the FORWARD II trial,1Amit M. Oza, MD, MBBS, concluded that bevacizumab and mirvetuximab soravtansine was a “very well tolerated and effective” combination with “encouraging activity,” even in patients previously treated with bevacizumab and weekly paclitaxel. Dr. Oza is Head ...
Bringing Palliative Care to Native American Patients With Cancer
Native Americans are among the most underserved minority populations in the United States and are disproportionately affected by cancer. They have the lowest survival rates for nearly all types of cancer of any minority population and much higher rates of certain types of cancer, including lung,...
Bridging the Gender Gap in Oncology
Women account for a growing proportion of the oncology workforce. Multiple studies, however, show that women oncologists are underrepresented in leadership positions, may have significantly lower salaries than men, and may be subjected to discriminatory practices stimulated by a medical culture...
Expert Point of View: Philip McCarthy, MD
Commenting on the updated results of the MAIA trial1 for The ASCO Post was Philip McCarthy, MD, Professor of Oncology and Internal Medicine and Director of the Transplant and Cellular Therapy Center at Roswell Park Comprehensive Cancer Center, Buffalo, New York. Dr. McCarthy described how the...
Role of PI3K Inhibition in Indolent Lymphomas
As reported by Fowler et al in the Journal of Clinical Oncology1—and summarized in this issue of The ASCO Post—the international phase IIb UNITY-NHL trial of 208 patients with marginal zone lymphoma (MZL; n = 69), follicular lymphoma (FL; n = 117), and small lymphocytic lymphoma (SLL; n = 22)...
Impact of COVID-19 on Cancer Treatment and Early Detection: Data-Driven Insights
From a dramatic drop in caseloads to missed screenings and diagnoses as well as the emergence of telemedicine, COVID-19 turned the world of oncology upside down. During the National Comprehensive Cancer Network (NCCN) Virtual Oncology Policy Summit, “Defining the ‘New Normal’ 2021 and the State of...
Implementation of a Program Providing Free Cancer Screenings, Same-Day Results
Evidence shows that early detection and treatment of cancer can significantly improve health outcomes. However, women in Mississippi—particularly in underserved populations—experience high rates of late-stage cancer diagnoses. A report published by Michelle Williams, PhD, and colleagues in the...
Study Identifies MET Amplification as a Driver for Some Non–Small Cell Lung Cancers
A study published by D. Ross Camidge, MD, PhD, and colleagues in the Journal of Thoracic Oncology has helped to define MET amplification as a rare but potentially actionable driver for non–small cell lung cancer (NSCLC). Dr. Camidge said many of the major developments in the treatment of NSCLC have ...
Study Explores Ketogenic Diet and Intermittent Fasting in Patients With Brain Cancer
More research into the efficacy of a modified ketogenic diet may be beneficial for people with brain tumors, according to a new study published by Schreck et al in the journal Neurology. The diet, which is high in fat and low in carbohydrates, led to changes in the metabolism in the body and the...
Expert Point of View: Jason J. Luke, MD
The invited discussant of LEAP-004, Jason J. Luke, MD, Associate Professor of Medicine and Director of the Cancer Immunotherapeutics Center, University of Pittsburgh Hillman Cancer Center, said the investigators of LEAP-0041 deserve credit for designing a study with a clearly defined...
ASCO and COA Jointly Release Oncology Medical Home Standards
Today, ASCO and the Community Oncology Alliance (COA) jointly released new Oncology Medical Home (OMH) standards, which provide a comprehensive roadmap for oncology practices to deliver high-quality, evidence-based cancer care. These standards, which were published by Woofter et al in JCO Oncology...
